Alexion 'Misled' USPTO About Blood Drug Patent, PTAB Says
The Patent Trial and Appeal Board has instituted review of an Alexion blood medication patent after finding that the company "misled" a U.S. Patent and Trademark Office examiner by providing "incomplete...To view the full article, register now.
Already a subscriber? Click here to view full article